TCL Archive Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials September 26, 2014
TCL Archive In Brief: NCI Gets $867 Million From Conferees; Grants To Be Funded At 41-42% Including Some Holdovers July 29, 1977